Obesity Clinical Trials in Miami, Florida
24 recruitingMiami, Florida
Showing 1–20 of 24 trials
Recruiting
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled759 locationsNCT07037433
Recruiting
Phase 3
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Obesity and Overweight
Metsera, a wholly owned subsidiary of Pfizer3,500 enrolled196 locationsNCT07311850
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,980 enrolled173 locationsNCT07321886
Recruiting
Phase 1
A Study of LY3971297 in Healthy Participants
ObesityHypertensionHealthy
Eli Lilly and Company225 enrolled7 locationsNCT06148272
Recruiting
Phase 3
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
ObesityOverweight
Eli Lilly and Company600 enrolled35 locationsNCT07357415
Recruiting
Phase 3
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
ObesityOverweightOverweight and/or Obesity
Pfizer999 enrolled184 locationsNCT07400653
Recruiting
Phase 1
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
ObesityHealthyOverweight+1 more
Eli Lilly and Company216 enrolled6 locationsNCT06945419
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,035 enrolled159 locationsNCT07282600
Recruiting
Phase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Crohn's DiseaseObesity or Overweight
Eli Lilly and Company290 enrolled187 locationsNCT06937099
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
ObesityOverweightSleep Apnea, Obstructive
Eli Lilly and Company800 enrolled123 locationsNCT07369011
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
ObesityOverweight
Eli Lilly and Company900 enrolled178 locationsNCT07392190
Recruiting
Phase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ulcerative ColitisObesity or Overweight
Eli Lilly and Company350 enrolled191 locationsNCT06937086
Recruiting
Not Applicable
Spinal Cord Injury Model Systems (SCIMS) - Education Module
ObesityCardiometabolic SyndromeSpinal Cord Injuries
University of Miami250 enrolled3 locationsNCT06003686
Recruiting
RESCUE: Discontinuation of GLP-1
Obesity
Boston Scientific Corporation150 enrolled3 locationsNCT07190794
Recruiting
Not Applicable
With Love, Grandma ("Con Cariño, Abuelita") Pilot Study
ObesityCancer, BreastCancer, Uterus+3 more
University of Miami Sylvester Comprehensive Cancer Center60 enrolled1 locationNCT05721976
Recruiting
Community Park-Based Programs for Health Promotion: Active Older Adults Prospective Cohort Study
ObesityCardiovascular DiseasesSedentary Behavior+3 more
Duke University1,000 enrolled1 locationNCT06604650
Recruiting
Community Park-Based Programs for Health Promotion: Fit2Play Prospective Cohort Study
ObesityPsychologicalDepression+6 more
Duke University5,000 enrolled1 locationNCT06595251
Recruiting
Community Park-Based Programs for Health Promotion: The Fit2Lead Prospective Cohort Study
HypertensionAnxietyPrehypertension+3 more
Duke University1,000 enrolled1 locationNCT06596265
Recruiting
Not Applicable
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
CancerSurvivorshipObesity, Childhood
University of South Florida520 enrolled10 locationsNCT04656496
Recruiting
Not Applicable
RESET System Pivotal Trial (Rev F)
ObesityDiabetes type2
Morphic Medical Inc.264 enrolled7 locationsNCT04101669